These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 38213287)
21. Down-regulation of Leishmania donovani trypanothione reductase by heterologous expression of a trans-dominant mutant homologue: effect on parasite intracellular survival. Tovar J; Cunningham ML; Smith AC; Croft SL; Fairlamb AH Proc Natl Acad Sci U S A; 1998 Apr; 95(9):5311-6. PubMed ID: 9560272 [TBL] [Abstract][Full Text] [Related]
22. The parasite-specific trypanothione metabolism of trypanosoma and leishmania. Krauth-Siegel RL; Meiering SK; Schmidt H Biol Chem; 2003 Apr; 384(4):539-49. PubMed ID: 12751784 [TBL] [Abstract][Full Text] [Related]
23. Identification of 3-Methoxycarpachromene and Masticadienonic Acid as New Target Inhibitors against Trypanothione Reductase from Maamri S; Benarous K; Yousfi M Molecules; 2021 Jun; 26(11):. PubMed ID: 34206087 [TBL] [Abstract][Full Text] [Related]
24. Footprinting of inhibitor interactions of in silico identified inhibitors of trypanothione reductase of Leishmania parasite. Venkatesan SK; Dubey VK ScientificWorldJournal; 2012; 2012():963658. PubMed ID: 22550471 [TBL] [Abstract][Full Text] [Related]
25. Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs. Chan C; Yin H; Garforth J; McKie JH; Jaouhari R; Speers P; Douglas KT; Rock PJ; Yardley V; Croft SL; Fairlamb AH J Med Chem; 1998 Jan; 41(2):148-56. PubMed ID: 9457238 [TBL] [Abstract][Full Text] [Related]
26. Optimization of Potent and Specific Trypanothione Reductase Inhibitors: A Structure-Based Drug Discovery Approach. Battista T; Federico S; Brogi S; Pozzetti L; Khan T; Butini S; Ramunno A; Fiorentino E; Orsini S; Di Muccio T; Fiorillo A; Exertier C; Di Risola D; Colotti G; Gemma S; Ilari A; Campiani G ACS Infect Dis; 2022 Aug; 8(8):1687-1699. PubMed ID: 35880849 [No Abstract] [Full Text] [Related]
27. Molecular mechanism underlying antileishmanial effect of oxabicyclo[3.3.1]nonanones: inhibition of key redox enzymes of the pathogen. Saudagar P; Saha P; Saikia AK; Dubey VK Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):569-77. PubMed ID: 24002022 [TBL] [Abstract][Full Text] [Related]
28. Dual-target drugs against Leishmania donovani for potential novel therapeutics. Bora K; Sarma M; Kanaujia SP; Dubey VK Sci Rep; 2023 Oct; 13(1):18363. PubMed ID: 37884555 [TBL] [Abstract][Full Text] [Related]
29. Identification of Novel Antileishmanial Chemotypes By High-Throughput Virtual and In Vitro Screening. Khan H; Hakami MA; Alamri MA; Alotaibi BS; Ullah N; Khan R; Khalid A; Abdalla AN; Wadood A Acta Parasitol; 2024 Sep; 69(3):1439-1457. PubMed ID: 39150581 [TBL] [Abstract][Full Text] [Related]
30. Proteome mapping of the protozoan parasite Leishmania and application to the study of drug targets and resistance mechanisms. Drummelsmith J; Brochu V; Girard I; Messier N; Ouellette M Mol Cell Proteomics; 2003 Mar; 2(3):146-55. PubMed ID: 12644573 [TBL] [Abstract][Full Text] [Related]
31. Ebsulfur is a benzisothiazolone cytocidal inhibitor targeting the trypanothione reductase of Trypanosoma brucei. Lu J; Vodnala SK; Gustavsson AL; Gustafsson TN; Sjöberg B; Johansson HA; Kumar S; Tjernberg A; Engman L; Rottenberg ME; Holmgren A J Biol Chem; 2013 Sep; 288(38):27456-27468. PubMed ID: 23900839 [TBL] [Abstract][Full Text] [Related]
32. Improved tricyclic inhibitors of trypanothione reductase by screening and chemical synthesis. Richardson JL; Nett IR; Jones DC; Abdille MH; Gilbert IH; Fairlamb AH ChemMedChem; 2009 Aug; 4(8):1333-40. PubMed ID: 19557801 [TBL] [Abstract][Full Text] [Related]
33. Biophysical and folding parameters of trypanothione reductase from Leishmania infantum. Shukla AK; Patra S; Dubey VK Appl Biochem Biotechnol; 2011 Sep; 165(1):13-23. PubMed ID: 21445596 [TBL] [Abstract][Full Text] [Related]
34. Epigallocathechin- Inacio JDF; Fonseca MS; Limaverde-Sousa G; Tomas AM; Castro H; Almeida-Amaral EE Front Cell Infect Microbiol; 2021; 11():640561. PubMed ID: 33842389 [No Abstract] [Full Text] [Related]
35. High-throughput virtual screening and quantum mechanics approach to develop imipramine analogues as leads against trypanothione reductase of leishmania. Pandey RK; Verma P; Sharma D; Bhatt TK; Sundar S; Prajapati VK Biomed Pharmacother; 2016 Oct; 83():141-152. PubMed ID: 27470561 [TBL] [Abstract][Full Text] [Related]
36. Small Molecule-Peptide Conjugates as Dimerization Inhibitors of Revuelto A; López-Martín I; de Lucio H; García-Soriano JC; Zanda N; de Castro S; Gago F; Jiménez-Ruiz A; Velázquez S; Camarasa MJ Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358115 [TBL] [Abstract][Full Text] [Related]
37. Structural insights into the enzymes of the trypanothione pathway: targets for antileishmaniasis drugs. Colotti G; Baiocco P; Fiorillo A; Boffi A; Poser E; Chiaro FD; Ilari A Future Med Chem; 2013 Oct; 5(15):1861-75. PubMed ID: 24144416 [TBL] [Abstract][Full Text] [Related]
38. Identification of chalcone-based antileishmanial agents targeting trypanothione reductase. Ortalli M; Ilari A; Colotti G; De Ionna I; Battista T; Bisi A; Gobbi S; Rampa A; Di Martino RMC; Gentilomi GA; Varani S; Belluti F Eur J Med Chem; 2018 May; 152():527-541. PubMed ID: 29758517 [TBL] [Abstract][Full Text] [Related]
39. Thiadiazine-thiones as inhibitors of leishmania pteridine reductase (PTR1) target: investigations and in silico approach. Shtaiwi A J Biomol Struct Dyn; 2024 Oct; 42(16):8588-8597. PubMed ID: 37578348 [TBL] [Abstract][Full Text] [Related]